Tick-Borne Encephalitis Vaccine (Ticovac)
Tick-Borne Encephalitis Vaccine is an FDA-licensed reference biologic from Pfizer Ireland Pharmaceuticals Unlimited Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2021
Reference approved
Reference product
Ticovac Tick-Borne Encephalitis Vaccine
Pfizer Ireland Pharmaceuticals Unlimited Company
- Approved
- Aug 13, 2021
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Tick-Borne Encephalitis Vaccine, in chronological order.
Reference approval
Approval date of the reference Tick-Borne Encephalitis Vaccine product.
4 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for Tick-Borne Encephalitis Vaccine (Ticovac)?
No 351(k) biosimilars or interchangeable biosimilars referencing Tick-Borne Encephalitis Vaccine are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.